RICHMOND, Virginia — FUJIFILM Wako Chemicals U.S.A., Corporation announces the launch of a ready-to-use small molecule cocktail comprising of Chroman 1, Emricasan, Polyamines, Trans-ISRIB (CEPT Cocktail), a chemical platform for stress-free cell culture and superior survival of induced pluripotent stem cells (iPSCs). CEPT Cocktail is intended for commercial research-use of iPSC applications including disease modeling, organoid generation, drug discovery, toxicology, and pharmacological studies. [Read more…]
Stem Cell News
BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.
As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.
Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.
Axol Bioscience signs exclusive agreement with The Francis Crick Institute to license iPSC technology
Today, The Francis Crick Institute signed an agreement giving Axol Bioscience exclusive rights to a methodology to generate human pluripotent stem cell (hPSC) derived cells used in drug screening and cardiotoxicity assays.
The technology developed by the Crick is used to generate near-homogeneous populations of hPSC derived left ventricular cardiomyocytes (LVCMs) with improved structural, functional and metabolic maturity. The initial discovery was protected, funded and further developed towards commercial application in-house at the Crick. This work has just been published in Cell Reports Methods and the intellectual property has been licensed to Axol Bioscience for both the production and supply of LVCMs, as well as the provision of screening services. [Read more…]
A new super factory with 29 GMP grade production lines for gene and cell therapy was launched in Shanghai by OBiO technology
SHANGHAI — On April 21, 2023, OBiO Technology (Shanghai) Corp., Ltd. (“OBiO” or “the Company”), a leading gene and cell therapy CDMO in China, announced the launching of a new GMP manufacturing base, named OBiO Intelli-M. The new base was located in the China (Shanghai) Pilot Free Trade Zone, Lin-Gang Special Area, with 29 production lines and 828,000+ square feet in area, which was one of the biggest super factories for gene therapy in the world. [Read more…]
Stem Genomics opens a local branch partnering with KaryoLogic to bring digital PCR and karyotyping services to North American clients
April 20, 2023 – Stem Genomics, a French biotech company specializing in innovative testing solutions for the quality control of stem cells for research and therapy, announces the opening of a US branch in the North Carolina Research Triangle region in a new partnership with global karyotyping expert, KaryoLogic Inc. The aim is to bring improved services for assessing the genomic integrity of human pluripotent stem cells (hPSC) to North American-based research scientists. [Read more…]
Gamida Cell Secures World’s 1st FDA Approval for an Expanded Cord Blood Cell Therapy
The FDA has approved Gamida Cell’s allogeneic cord blood cell therapy (Omisirge, formerly Omidubicel and NiCord) as a means to speed the recovery of white blood cells in cancer patients.
The approval is for a single intravenous dose of stem cells from a donor’s expanded umbilical cord blood that is processed and cultured with nicotinamide (a form of vitamin B3).
Omisirge produces faster neutrophil recovery and reduced infections compared to standard cord blood. The approval is based on a study of 125 subjects with blood cancer.Â
- « Previous Page
- 1
- …
- 51
- 52
- 53
- 54
- 55
- …
- 145
- Next Page »